Avacta Group Plc (LON:AVCT) hit a new 52-week low during trading on Tuesday . The stock traded as low as GBX 30 ($0.43) and last traded at GBX 31.50 ($0.45), with a volume of 24546 shares traded. The stock had previously closed at GBX 31.50 ($0.45).
Separately, FinnCap restated a “corporate” rating and set a GBX 200 ($2.86) target price on shares of Avacta Group in a research report on Monday, January 15th.
In related news, insider Alastair Smith bought 35,800 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were bought at an average cost of GBX 42 ($0.60) per share, for a total transaction of £15,036 ($21,529.21).
Avacta Group Company Profile
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.